BioSpace News Archive

Imvax, Inc ., an emerging oncology leader that is revolutionizing immunotherapy for patients with malignant glioblastomas (GBM) and other solid tumors with significant unmet medical needs, today announced the appointment of Wendy DiCicco to its board of directors.

First-of-its kind study to be supported by the Cura Foundation, The Marcus Foundation, Sanford Health and Alliance for Cell Therapy Now

- Treatment with olvimulogene nanivacirepvec (Olvi-Vec)-primed immunochemotherapy shows promising overall survival benefit in this heavily pretreated late-stage patient population - The majority of patients benefited from apparent reversal of platinum resistance with preserved or improved performance status - Olvi-Vec treatment was tolerated with safety results consistent with previous Phase 1b study

-- Next-generation gene editing company launched by Versant Ventures with additional backing by Samsara BioCapital -- -- Core technology from Stanford founders Matt Porteus and Maria Grazia Roncarolo -- -- Josh Lehrer joins as CEO -- SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Graphite Bio today announced a $45 million Series A financing led by founding investor Versant Ventures, together with Samsara BioCapital. Graphite Bio is

Havn Life Sciences Inc. is pleased to announce that it has been accepted to list its common shares on the Frankfurt Stock Exchange under the trading symbol.

PolarityTE, Inc. (Nasdaq: PTE) today announced cost per product data from the protocol-specified interim analysis in the Company’s ongoing randomized controlled trial (RCT) evaluating SkinTE for the treatment of diabetic foot ulcers (DFUs), which previously reported statistically significant wound closure rates of 72% for SkinTE plus the standard of care (SOC) vs 32% for the SOC alone (p=0.005).

Veteran IP attorney Nancy Chiu Wilker, Ph.D., J.D., joins leadership team as vice president of legal Company also secured $15 million from Oxford Finance to further support pipeline development

Varian (NYSE: VAR) has received notice from the Customs Tariff Commission of the State Council of China that the first exclusion of the additional tariffs China imposed on US products will expire on September 16, 2020 . In accordance with procedures, the exclusion will be extended by one year, from Septemb

The National Cancer Institute (NCI) and the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of the National Institutes of Health (NIH), have awarded physIQ a contract to develop an AI-based COVID-19 Decompensation Index (CDI) Digital Biomarker to address the rapid decline of high-risk COVID-19 patients.

Regional CLIA-Certified Labs among Growing Number of Customers Expanding SARS-CoV-2 Testing with Fluidigm Technology